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Abstract 
Microbeam Radiation Therapy (MRT) exploits tumour selectivity and normal tissue sparing with 
spatially fractionated kilovoltage X-ray microbeams through the dose volume effect. Experimental 
measurements with Ta2O5 nanoparticles (NPs) in 9L gliosarcoma treated with MRT at the 
Australian Synchrotron, increased the treatment efficiency.  Ta2O5 NPs were observed to form 
shells around cell nuclei which may be the reason for their efficiency in MRT. In this article, our 
experimental observation of NP shell formation is the basis of a Geant4 radiation transport study to 
characterise dose enhancement by Ta2O5 NPs in MRT. Our study showed that NP shells enhance 
the physical dose depending microbeam energy and their location relative to a single microbeam. 
For monochromatic microbeam energies below ~ 70 keV, NP shells show highly localised dose 
enhancement due to the short range of associated secondary electrons. Low microbeam energies 
indicate better targeted treatment by allowing higher microbeam doses to be administered to 
tumours and better exploit the spatial fractionation related selectivity observed with MRT. For 
microbeam energies above ~ 100 keV, NP shells extend the physical dose enhancement due to 
longer-range secondary electrons. Again, with NPs selectively internalised, the local effectiveness of 
MRT is expected to increase in the tumour.  Dose enhancement produced by the shell aggregate 
varied more significantly in the cell population, depending on its location, when compared to a 
homogeneous NP distribution. These combined simulation and experimental data provide first 
evidence for optimising MRT through the incorporation of newly observed Ta2O5 NP distributions 
within 9L cancer cells.  
Keywords:  nanoparticle, microbeam radiation therapy, dose enhancement, Geant4. 
1. Introduction 
Cancer remains one of the leading causes of death worldwide. Amongst other treatment methods, such as 
surgery and chemotherapy, the use of radiation in the treatment of cancer remains the most prominent and 
successful modality [1]. The sensitive treatment of brain tumours (such as inoperable gliomas and 
gliosarcomas), with wide, and unsegmented radiotherapeutic beams, impart unavoidable yet clinically 
unacceptable damage to vital central nervous system (CNS) tissues [2,3]. Microbeam radiation therapy 
(MRT) may provide a solution to this challenge.  
 
MRT involves the application of an array of spatially fractionated microbeams sourced from third 
generation synchrotrons, with beam widths ranging from 25 to 75 µm, and a pitch of 200-400 µm [2-15].  
The energy of these beams lie within the kilovoltage X-ray range of 50-175 keV, as first outlined by 
Slatkin et al. [4]. Microbeam peak doses of between 500-1000 Gy can be delivered safely due to the well-
known dose volume effect [5-8]. 
 
The treatment quality of MRT is assessed by the peak-to-valley dose ratio (PVDR), which describes the 
ratio between the in-beam dose to the out-of-beam dose at mid distance between two adjacent 
microbeams. The peak doses are typically 20-100 times higher than the valley [5,6,7].  Small PVDRs 
indicate that the valley dose between adjacent microbeams, is large in relation to the peak dose. When 
made comparable to the large peak doses, this indicates better tumour coverage [7,8]. Conversely, a large 
PVDR and small valley dose may be more accommodating for tissue recovery, allowing normal tissue to 
be spared through the dose-volume effect [5-8].   
 
The key advantage of MRT arises from the reported increase in sensitivity of tumour tissue to the 
microbeam array, which differs to the observed recovery of normal tissue [9-17].  Radiation treatments 
for radioresistant tumours such as gliomas, require extremely high absorbed doses [15,16], yet with their 
development in sensitive brain tissue, large doses cannot be administered without significant damage. 
MRT becomes a preferable option as tumour control is maintained, and normal tissue can withstand high 
radiation doses when delivered in small volumes [9,10]. Some pre-clinical trials note the development of 
minor cerebral oedemas following MRT [18]. However, the oedemas disappear within a week after the 
MRT treatment, in agreement with studies that highlight the success of normal tissue sparing with MRT 
[9-17]. 
 
The effectiveness of MRT as a selective cancer treatment is yet to be understood completely. 
Radioresistant brain tumours, such as 9L gliosarcoma, are seen to be more effectively treated with MRT 
than broad beams due to large peak doses [15,16]. Crosbie et al. [11], indicates that there is a significant 
difference in the migration of tumour cells in comparison to the normal cells. This may increase the 
probability of cellular communications to initiate widespread apoptosis [12,14]. This, and extreme 
damage to local tumour vasculature [13], may provide a reason for the success of spatially fractionated 
beams to control radioresistant tumours. Therefore, the future applications of MRT are aimed at treating 
brain tumours. There is good prognosis for child brain cancers, with less risk of damage to the developing 
CNS than conventional broad beams [18].  
 
High-Z nanoparticles (NPs) have been shown to improve the effectiveness of dose conformity to tumour 
tissue in the case of conventional unsegmented kilovoltage X-rays [19-30]. The advantages of NPs, 
besides the primary benefit of enhancing tumour radiosensitivity, often include biocompatibility, 
permeability to cell membranes due to their nano-scale dimensions, ability to specifically target certain 
tumours when coated and actively accumulate at tumour sites with leaky vasculature [21,22].  
 
In MRT, NPs may be useful by raising the local dose to the tumour, in particular to enhance the low 
valley dose at the site of the tumour [7].  NP use may in turn promote more normal tissue sparing, as peak 
doses could be lowered to induce the same clinical treatment outcome.  This potential has been 
demonstrated by Rahman et al. [27], showing that in the presence of gold NPs (GNPs), the necessary 
dose delivered by MRT to kill endothelial cells can be reduced by 10 Gy. Martínez-Rovira et al. [7] 
demonstrated through Geant4 simulations, that GNPs enhanced the valley dose and produce significant 
decreases in the PVDR at the site of the tumour. This translates in a reduced dose in the healthy tissue, 
limiting possible collateral effects. 
 
Tantalum pentoxide (Ta2O5) NPs are a non-toxic, nano-structured ceramic compound. Their use as a 
radiosensitizer was first reported by Brown et al. [28] in conventional X-ray radiotherapy. These nano-
structured ceramic particles have different aggregation properties than inert metal NPs. In particular, they 
tend to form shell aggregates instead of distributing homogeneously in the medium, producing different 
physical dose enhancements [29].  
 
Geant4 simulations were performed by McKinnon et al. [29] to characterise the physical dose 
enhancement produced by different distributions of Ta2O5, as observed experimentally, for a 150 kVp 
broad beam. The shell structures produced large localised physical dose enhancements to surrounding 
cells using the kV broad beam, with large NP clusters up to 7 µm thick producing dose enhancement that 
is up to 100 times.  
 
Because of the promising outcome obtained for conventional kV radiotherapy, Ta2O5 NPs have great 
potential to enhance the clinical outcome of MRT. This article shows a Geant4 simulation study aimed to 
determine how the physical dose in MRT treatments can be optimised in a cell population with Ta2O5 
NPs. The use of NPs in MRT is a novel multi-modal approach named Synchrotron Microbeam Activated 
Radiation Therapy (SMART). This work was motivated by new experimental findings of our first cell 
survival experiments produced at the IMBL beamline of the Australian Synchrotron. 
 
2. Motivation of the Geant4 simulation study: Experimental Measurements 
This section summarises the first experimental measurements performed at the IMBL beamline of the 
Australian Synchrotron (AS) with tumorous 9L gliosarcoma cells and Ta2O5 nanoparticles, motivating the 
Geant4 simulation study of this work. The details of the radiobiological experiments will be object of a 
separate article.  
 
Ta2O5 NPs are nano-structured ceramic particles that have shown to enhance conventional kV and MV 
radiotherapy [29,30]. Ta2O5 NPs are manufactured according to Brown et al. [28] and added to the cell 
culture flask to incubate for 24 hours. The toxicity to the cells with concentrations of 50-500 µg/mL, after 
24 hrs incubation, was found to be very low, with cell clonogenic survival of 80-100% [28,30]. Therefore, 
there is no lethality towards cells besides that induced due to ionising radiation. 
 
Besides this low-toxicity, Ta2O5 NPs show great promise for treatments of these radio-resistant 
gliosarcomas, due to their inherent ability to internalise for long periods of time in 9L gliosarcoma. Figure 
2.1 demonstrates the results of a series of images of the 9L gliosarcoma cells taken after 15 hrs of 
incubation with Ta2O5 at the AS.  
 
Figure 2.1 Observed Ta2O5 NPs internalisation in experimental studies with 9L gliosarcoma cells: 
Clusters of nanoparticles (red) and smaller aggregates (green) are encompassed by the 9L cells (0.5 hr) 
and transported toward the cell nucleus (2-4 hrs) to form a clustering shell (these times are after 15hrs 
incubation). Flask NP concentration was 200 µg/mL. 
NPs are allowed into cells (endocytosis mechanisms, in particular phagocytosis, [26]), where they begin 
to aggregate with other clusters of Ta2O5.  With the observation of these NPs forming “shells” around 9L 
tumour cell nuclei, it was decided to investigate their efficacy in SMART and how dose enhancement is 
impacted by the NPs distribution considerations. 
 
For experimental studies, T12.5cm2 flasks with/without NPs were irradiated in a vertical orientation at AS 
IMBL hutch 1B, with a single dose (0.4 Gy in the valley), with a dose rate of 500 Gy/s in the peak, and 
average beam energy of 90 keV. MRT beams were 25 µm and 50 µm wide and pitch of 200 µm centre to 
centre Fig. 2.2 shows the normalised cell survival fraction in 9L cells with increasing NP concentrations 
in the flask. The results show that Ta2O5 NPs reduce the cell survival fraction in 9L cell lines irradiated 
with MRT.   
 
The physical dose enhancement due to NPs in a spatially fractionated and low energy radiation field may 
vary due to NP distribution, for the case of Ta2O5 NP shells in particular. For this reason, our Geant4 
simulation study aims to characterise what effect various sizes and positions the NP shells have on the 
SMART effectiveness. The results obtained with NP shell congregates are compared to a homogeneous 
solution of the same NP mass. The goal is to provide an insight into the physics behind the experimental 




with a lower PVDR in the tumour and a higher PVDR in normal tissue [7,8], to maximise clinical 
benefits. 
 
Figure 2.2: Cell clonogenic survival fraction for 9L gliosarcoma cell line, exposed to 50 µm wide 
microbeams with 200 µm pitch, at 0.4 Gy in the valley, with 50 and 500 µg/mL concentrations of Ta2O5 
NPs. Normalisation was done to the non-irradiated control. 
3. Methodology: The Geant4 simulation study 
Monte Carlo simulations were performed using Geant4, version 10.1 [31, 32]. The simulation set-up, 
shown in Fig. 3.1, consists of a water microscopic phantom (called here µ-phantom) with size 220 µm x 
70 µm x 40 µm. A mono-layer of cell nuclei, modelled as 8 μm diameter spheres of water, were included 
in the µ-phantom. The cell nuclei are 14 μm apart centre to centre, except in the penumbral region of the 
cell population, where the nuclei are 16 μm apart (between S5 and S6 in Fig.3.1 and 3.2).  
 
The µ-phantom was set normally to the beam direction, at 6 mm depth in a larger water phantom with 30 
cm side lengths and 10.6 cm length in the direction of incidence of the beam. A 50 µm wide microbeam 
was incident on the centre of the µ-phantom, with monochromatic energy spanning from 30 keV to 150 
keV, which is a typical energy range used for realistic MRT beams.  The case of a 50 µm wide photon 
beam was considered, as it was the same width used in experimental studies.   
 
In order to track secondary electrons down to 100 eV, and obtain shorter simulation execution times 
compared to the Geant4-DNA Low Energy Extensions, the Low Energy Electromagnetic Physics models 
based on PENELOPE [32-34] were adopted to describe particle interactions. Stewart et al. [33] showed 
that PENELOPE physics models can estimate physical quantities on the micron-scale between 1 and 25% 
50 µm 
agreement with track structure Monte Carlo codes when calculating the mean specific energy.  Auger 
electron emission and fluorescence are also modelled.  
The physical dose enhancement in the cells of µ-phantom was studied by placing one shell-like Ta2O5 NP 
congregate in different positions with respect to the incident microbeam and varying the energy of the 
incident photon beam.  Dose was calculated in individual cells.  
 
When the NP congregate was set in the peak position (at S8 in Fig. 3.1), the dose was calculated by 
doubling the statistics derived from the cells in symmetric positions, with respect to the axis of the 
microbeam (corresponding to S1-S8 in Fig. 3.1). The NP congregate was then substituted by a 
homogeneous solution of the same NP mass distributed in the water medium of µ-phantom, outside the 
cells.  
 
Figure 3.1:  Geant4 simulation set-up: the µ-phantom contains a cell (or cell nuclei) monolayer, 
modelled with 75 spheres with 8 μm diameter. The cross-section of the µ-phantom traversed by the MRT 
beam, the “peak region”, is indicated by the black rectangle. A side view of the monolayer is also shown 
on the right with the beam in the z-direction. The MRT photon beam is incident along z-axis. 
The Ta2O5 NP “shell” was modelled with thickness varying between 1 and 3 µm to reflect the average and 
maximum shell cluster thicknesses observed in experimental studies. The corresponding local NP 
concentrations in the µ-phantom, shown in Table 3.1, are consistent with the order of magnitude of the 
concentrations of the experiments at the level of the cells, though only 1 shell is considered at a time.  






% Mass of Ta2O5 NPs in the µ-
phantom 
Local concentration of NPs in  
the volume of µ-phantom(mg/mL) 
1 0.34 3.4 
2 0.84 8.5 
3 1.53 15.6 
 
The second study consisted of calculating the dose enhancement, moving the NP shell congregate from 
the peak (position S8 in Fig. 3.2) to the valley. In particular, the NP shell congregate was moved from the 
centre of the beam (P1) to the edge of the 50 µm beam (P2), the penumbral region (P3) and the valley 
region (P4). In this case, a 3 µm NP shell was modelled, as it produces the greatest amount of secondary 
electrons in photon interaction, due to its increased NP mass. In this set-up, the dose is calculated in each 
cell of the monolayer and averaged over the cells along each line (S1, S2, up to S15, see Fig. 3.2), as there 
is no symmetry with NP dose enhancement in this set-up.   
  
Figure 3.2: Alternative positions of the NP shells in the µ-phantom.  
The energy deposited in each cell was calculated and converted to dose per cell per incident photon, for 
cases with Ta2O5 NPs in shells, homogeneous solution, or without Ta2O5 (water only).  The physical dose 
enhancement was evaluated with the dose enhancement ratio (DER), which is the ratio of the absorbed 
dose per incident photon with Ta2O5 NPs present (DNP), to the absorbed dose in water without NPs (DW), 
in the same irradiation conditions: 
DER =  DNP / DW. 
The statistical uncertainty in the results obtained was determined by calculating the average and standard 
deviation of multiple simulations with different simulation random seeds. Any additional uncertainty in 
the simulation is a consequence of the uncertainty in physics models selected. 
4. Results 
4.1 Dose enhancement with the nanoparticle shell located in the microbeam peak 
The first study quantified the DER (defined in section 3) of the NP shell when it is located in the MRT 
peak (see Fig 3.1), and the energy of the incident microbeam is varied. The dose was integrated over the 
peak region (indicated by a black rectangular contour in Fig. 3.1). Fig. 4.1 shows the DER with respect 
to the energy of the incident monochromatic microbeam, and the effect of varying the NP shell 
thickness.  
                    
 
Figure 4.1: Average DER w.r.t. beam energy with Ta2O5 NPs distributed as a shell around the central 
cell, with varying shell thickness (see Table 3.1). Statistical uncertainty is present, though smaller than 
plotted data points. 
 It can be observed that average DERs in the peak region range between 2 and 7 depending on microbeam 
energy and NP shell thickness.  The thicker the shell, the higher the average DER. Although, the relative 
increase in DER is non-linear with respect to increasing shell thickness.  Thicker shells produce more 
secondary electrons in the NP, however, at the same time, the number of electrons escaping the NP 
reduces because of the higher probability of ionisation interactions, which increase electron absorption in 
the NP itself. The interplay between the two effects leads to an increase in DER, but the DER increase 
becomes less efficient, eventually reaching a saturation effect as described in McKinnon et al.  [29]. 
 
The optimum DER is produced for incident photon energies between 40 and 60 keV, depending on the 
shell thickness. This energy correlates to a maximum in photon absorption relative to water for Ta2O5, 
shown in Figure 4.2, which is dominant over the kV range.  
 
The 67.4 keV K-edge [34] in Ta2O5 did not produce a larger DER. This occurs because at the K-edge 
more electrons are produced in the NP, however the electrons reach the surrounding biological medium 
with a relatively lower LET. Instead, for an incident 40-60 keV beam, there is an optimal combination 
between the production cross section of secondary electrons in the NP, and their LET when reaching 
cellular nuclei.  
 
Figure 4.2: Ratio between the photon mass energy coefficients of Ta2O5 and water [34]. 
 
The dose in the entire µ-phantom was calculated with and without the NP shell set in the centre of the 
beam, with a varying incident monochromatic energy between 50 keV and 150 keV. The Ta2O5 shell 
thickness is varied between 1 and 3 μm. Fig 4.3 shows the results obtained for the lowest and highest 
energy of the incident photon beam, 50 keV and 150 keV, respectively.   
It can be observed that the presence of a NP shell produces long-range dose enhancement depending on 
the energy of the photon beam. The peak dose is best enhanced for 50 keV photons (see Fig. 4.1) due to 
 
        (A)                                                                                      (B)  
         
Figure 4.3: Dose per incident photon calculated in the cell nuclei of the µ-phantom, with respect to the 
distance from the beam centre. (A): The energy of the incident photon beam is 50 keV; (B): The energy of 
the incident photon beam is 150 keV. 
short-range, high LET photoelectrons. However, there is no increase of dose in the valley due to the 
limited range of the electrons.   
 
At 150 keV, a higher dose in the valley at 100 µm from the peak is observed. This occurs because more 
energetic electrons are produced by the NP shell, which are able to reach the valley and contribute to the 
dose enhancement.  Electrons with energy above 90 keV have a range in water larger than 100 µm, as 
shown in Table 4.1, [35]. 
Fig. 4.4 shows the DER with respect to the distance from the centre of the beam in the µ-phantom, due to 
a 3 µm NP shell for 50 keV, 70 keV and 150 keV microbeams.  The simulation set-up used is shown in 
Fig 3.1.  
 
Table 4.1 CSDA (Continuous Slowing Down Approximation) range of electrons in Ta2O5 and water [35].  
Electron Energy 
(keV)  
Range in Water 
(µm) 
Range in Ta2O5 
(µm) 
10 2.5 0.74 
20 8.6 2.25 
30 17.6 4.4 
40 29.2 7.1 
50 43.2 10.3 
60 59.4 13.9 
70 77.6 18.0 
80 97.7 22.4 
90 119.6 27.2 
100 143.1 32.3 
 
 
Figure 4.4: DER due to a 3 µm NP shell in the centre of the microbeam as a function of distance from the 
microbeam centre with selected photon energies. 
It can be observed that the DER depends on the energy of the incident beam. For each photon energy, the 
DER has a first maximum in the centre of the beam and, for higher photon energies, a second maximum  
at the edge of of the beam or in the valley. The position of the second maximum depends on the incident 
beam energy and the corresponding kinetic energy distribution of the secondary electrons produced in the 
NP, which reach the valley with different LETs. 
 
Considering the two extreme cases, the 50 keV photon beam has the highest DER in the MRT peak, while 
the 150 keV photon beam has the maximum DER in the valley. In the first case, secondary electrons 
originated in the NP have lower energies, therefore they contribute to the DER closer to the NP (the 
maximum distance which can be travelled in water is 40 µm, Table 4.1). In the second case, secondary 
electrons have more kinetic energy, therefore travel longer distances and deposit energy in the valley 
because of their higher LET in this region.  
 
A 70 keV microbeam targeting the K-edge of Ta2O5 (see Figure 4.2), produces a lower DER than 50 keV 
and 150 keV beams in the peak and in the valley, respectively. This again is explained by the kinetic 
energy distribution of the secondary electrons, which produce a maximum in DER at the edge of the 
beam.   
 
The effect of increasing the NP shell thickness, when the shell is present in the peak, results in an increase 
of the DER, as indicated by Fig. 4.5 and shown in Figure 4.5.  
 
   
Figure 4.5: DER dependence on energy and NP shell thickness as a function of distance from the centre 
of the microbeam. 
The DER increases with growing shell thickness, and this is also energy dependent. There is a (125 ± 
10)% increase in the valley dose from a 1 µm to 3 µm NP shell with 150 keV beam, in contrast to 0% 
DER increase for the 50 keV beam. The rise in valley %DER with increasing shell thickness is due to the 
increase surface-to-volume ratio of the NP congregate.   
The peak DER is largest with the lower energy beam, however, increasing the NP thickness results in a 
less efficient increase in the DER for 50 keV with respect to the 150 keV beam. This is because the NP 
shell is more likely to absorb the higher LET electrons produced by the low energy beam. 
 
4.2 Dose enhancement when the nanoparticle is set in the microbeam valley 
Fig. 4.6 shows the DER obtained by moving the NP shell from the beam centre to other positions in or 
out of the microbeam. These positions are labelled in Fig. 4.6 as defined in Fig. 3.2. As expected, the NP 
shell produces dose enhancement in any position where it is located. The DER depends strongly on the 






Figure 4.6: DER to cell population with NP shell located at various locations in the peak (P1), edge of 
beam (P2), mid-valley (P3) and valley (P4) as in Fig 3.2, and exposed to 50 keV (A), 150 keV (B) 
microbeam.        
 
A 50 keV microbeam tends to produce highly localised dose enhancement, with DER values reaching 52 
at maximum. In particular, the dose enhancement is limited to the cell nucleus that the NP cluster 
surrounds and the closest neighbouring cell nuclei. Even if a DER of approximately 52 is observed in the 
valley, the dose in this region is low. For example the dose calculated in the valley with NPs, at 100 µm 
distance from the centre of the peak is (0.17 ± 0.08)×10-11 Gy and (1.5 ± 0.1)×10-11 Gy per incident 
photon, for 50 and 150 keV photon beam, respectively. 
 
With a 150 keV beam, lower DER values are observed overall when compared to a 50 keV beam, 
however the maximum dose enhancement occurs at greater distances from the NP shell (with DER up to 
17). The highest DER in the valley is observed with the NP shell set in the MRT peak, and the DER 
reduces when the NP is set at larger distances from the beam centre.  
 
4.3.  MRT dose enhancement in a homogeneous solution of nanoparticles 
Fig. 4.7 and 4.8 show the dose per incident photon and the DER, respectively, plotted against the distance 
from the beam centre. A shell congregate of 3µm thickness, set in the microbeam peak or valley, was 
compared to a corresponding solution of Ta2O5 throughout the cell population. The solution has the same 
total concentration of  Ta2O5 as the NP shell (shown in Table 3.1). Results are shown for a 50 keV and 
150 keV incident photon energy. 
 
When the NPs are distributed in a solution throughout the entire µ-phantom, the dose expectedly has no 
dependence on the congregation characteristics of the NP. This is reflected in the results of Fig. 4.7. For a 
50 keV photon beam, the NP shell causes a larger dose in the peak than the corresponding homogeneous 
distribution because of the more localised dose enhancement in the peak and proximity to a greater 
density of NPs. When increasing the distance from the beam centre, the dose produced by the solution 
becomes larger than in the NP shell case. This occurs because secondary electrons can be produced 
throughout the µ-phantom due to the many NP targets, contributing to the dose locally at the point of 
generation. As a result, the DER produced by a NP solution is larger than the DER obtained with the NP 
shell located in the microbeam peak (see Fig. 4.8).  
When the microbeam energy is lower (below 70 keV), a NP shell located in the valley produces a higher 
local DER than a homogeneous NP distribution due to enhanced local emission of high LET electrons 
depositing energy locally in the valley.  
 
 
(A)                                                                    (B) 
  
Figure 4.7: Physical dose per incident photon with respect to distance from the centre of the microbeam 
for NPs distributed as a 3 µm shell in the peak (A) and in the valley (B), compared to NPs distributed 
homogeneously (15.6 mg/mL concentration) with selected incident photon energies (50 and 150 keV). 
 
 (A)                                                                           (B)  
   
Figure 4.8: DER due to homogeneously distributed NPs (15.6 mg/mL), compared to a 3 µm NP shell in 
the microbeam peak (A) and in the valley (B) as a function of distance from the microbeam centre with 
selected incident photon energies (50 and 150 keV). 
 
When the microbeam has a higher energy, such as 150 keV, the dose and the DER of a NP shell set in the 
peak are higher than the configuration of homogeneous solution. This occurs because the NP shell 
produces long-range dose enhancement and the probability of interaction with NPs located in the path of  
the incident beam is maximised with respect to the NP solution. When, instead, the NP shell is located in 
the valley, the associated dose and DER are similar to the homogeneous solution. This happens because 
the microbeam has lower probability of interaction with the NP shell when it is located in the valley.  
 
4.4  MRT peak to valley dose ratio with Ta2O5 nanoparticles 
The peak-to-valley dose ratio (PVDR) is often used as an indication of the quality of a MRT treatment 
[4]. In this study, we have evaluated the PVDR for the case with and without NPs. Figure 4.9 shows the 
PVDR with respect to the photon beam energy without NPs, with NPs homogeneously distributed, and 
with the NP shell set in the MRT peak or valley. A shell thickness of 3 µm was selected to obtain higher 
DER. 
 
The PVDR was measured for locations P1-4 as shown in Fig. 3.2. For any photon beam energy, the 
PVDR is largest and smallest when the NP shell is located in the centre of the beam and in the valley, 
respectively as shown in Fig. 4.9. This is due to the interplay between the probability of interaction of the 
NPs with the incident beam (which is expectedly greater in the peak), and the kinetic energy spectra of 
the secondary electrons produced. Overall, the PVDR decreases when the NP shell is placed further from 
the peak with respect to water. 
 
The largest PVDR in water is obtained for lower beam energies, due to the short-range photoelectrons 
produced in the peak that do not reach the valley. This indicates the greatest potential for tissue sparing, 
with overall low valley doses relative to the peak. There is also highly localised dose enhancement 
obtained at low beam energies with NP shells, as shown in Fig. 4.6A. Therefore, the PVDR is larger than 
the one calculated for water when the NP is located in the peak, and smaller when the NP shell is located 
in the valley.  
When instead the NP shell is set in the valley, the PVDR is always lower with respect to the case of a 
homogeneous solution, except at 150 keV, where instead the PVDRs are similar.  
The PVDR calculated with the NP distributed homogeneously was found to always be equal to, or less 
than the PVDR calculated in water without NPs, in agreement with Martinez-Rovira et al. [5]. This 
occurs because secondary electrons can be produced in the NP material located throughout the entire µ-
phantom, including the valley, and results in a reduction in the PVDR.  
The PVDR calculated with the NP solution is therefore always lower than the PVDR calculated with the 
NP shell set in the peak, for any energy of the incident photon beam.  
These results emphasize how the congregation properties of NPs play a crucial role in determining the 
PVDR.   
 
 
Figure 4.9: PVDR with respect to the photon beam energy, calculated in water without NP (crosses), with 
a NP homogeneous solution (black circles) and with a 3 µm NP shell set in the centre of the MRT peak or 
valley (diamonds). 
 
5. Discussion and conclusion 
This study investigated the physical dose enhancement produced by Ta2O5 NP shells in MRT using a 
simplified configuration, where one single NP congregation was located in different positions in the 
MRT peak and valley, and compared to homogeneously distributed NPs. This study showed that NP 
dose enhancement for SMART is highly dependent on the NP congregation properties, location of 
congregations with respect to the beam peak, and photon energy. 
 
The NP dose enhancement was found to increase with the NP shell thickness because of the higher 
probability of generating secondary photoelectrons, and was found to be dependent on the energy of the 
incident photon beam, as expected. In the case of a photon beam below 70 keV, the DER is mainly 
localised to the NPs, and in particular the cell nucleus surrounded by the NP shell and in the adjacent cell 
nuclei. When the photon beam energy increases, there are long-range effects, producing significant dose 
enhancement at some distance from the NP, due to the greater range of secondary electrons.  
 
The DER is maximised for lower photon energies because of the increase in the photoelectric effect 
cross-section. The maximum DER obtained with a 50 keV photon beam is approximately 45 when the 
NP is located in the MRT peak.  With the NP shell located in the valley, the maximum DER was similar 
at 52. With the NP shell is located in the valley, the DER in the valley is generally much higher with low 
energy beams because of the localised energy deposition. As a result, the PVDR has its minimum in this 
configuration, and only approaches the PVDR without NPs when the beam energy increases. 
 
Overall, the NP shell proved to be useful in enhancing the dose to the population of cells over a large 
range of beam energies when located either in the MRT peak or in the valley.  A homogeneous NP 
solution showed a less variable DER throughout the µ-phantom and across all microbeam energies with 
respect to the NP shell, as expected, because of the uniform distribution of NPs in the medium. The NP 
homogeneous solution produces a lower PVDR than the case without NPs, across all energies. 
Table 5.1 summarises the doses in the peak and valley for a set of NP congregation properties and 
energies. These results demonstrate that the NP distribution properties are crucial in determining the 
dose enhancement ratio and PVDR, and therefore must be taken into account to optimise the MRT 
treatment with NPs. The highest valley dose is produced with a NP shell in the valley at low energies. 
This is followed by 150 keV beam incident on a NP shell to produce significant NP dose enhancement, 
independently from the location of the NP shell with respect to the microbeam. The NP homogeneous 




Table 5.1 Summary of physical dose per incident photon (Gy) due to microbeam energies of 50 keV and 
150 keV, comparing NP shell and NP solution results in the peak and valley. The grey cells indicate the 
configurations with the largest dose in the peak and in the valley of the microbeam. 
 50 keV 150 keV 
Peak Valley Peak Valley 
No NP (5.59 ± 0.06)×10-9 (1.7 ± 0.8)×10-12 (11.71 ± 0.07)×10-9 (15 ± 1)×10-12 
3 µm NP shell 
at P1 
(251.5 ± 0.2)×10-9 (2.8 ± 0.6)×10-12 (69.6 ± 0.1)×10-9 (55 ± 4)×10-12 
3 µm NP shell 
at P4 
(5.59 ± 0.06)×10-9 (89 ± 5)×10-12 (11.66 ± 0.06)×10-9 (38 ± 4)×10-12 
15.6 mg/mL 
homogeneous 
(11.80 ± 0.09)×10-9 (3.3 ± 0.6)×10-12 (12.59 ± 0.06)×10-9 (30 ± 3)×10-12 
 
The results of this study indicate that both the NP distribution and microbeam energy must be considered 
for efficient NP dose enhancement. MRT beams with energy range below the K-edge of Ta (~70 keV), 
may be adopted to reduce collateral effects to healthy tissues, due to the largest PVDR in water. 
Furthermore, the significant local dose enhancements produced by selective NP shells in tumour cells via 
the increased production of higher LET electrons, give good prognosis for tumour control. With a 
selective internalisation in the tumour cells, higher target doses may be delivered to the tumour, which is 
beneficial for effective treatment of radioresistant cancers [5,16,17]. 
 
Another possible solution is to instead adopt a higher energy photon beam (above ~ 100 keV), which 
reduces the PVDR with NPs both homogeneously distributed and with NP shells. This solution may be 
more beneficial to achieve a better coverage of the tumour, particularly for homogeneous NP 
distributions, while eventually reducing the overall dose administered to the patient.  
 
In order to further investigate the optimal energy of the photon beam, future simulation work will 
investigate the DER and PVDR in a more realistic scenario in terms of shell distribution throughout the 
entire cell population.  The effect of multiple microbeams will be investigated as well as the effect of 
different peak-to-peak spacing and beam widths. The simulation study will be integrated with 
radiobiological measurements at the AS using low microbeam energies to quantify NP sensitisation. 
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